thalidomide has been researched along with Epithelial Neoplasms in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide has dual antiangiogenic and immunomodulatory properties and confirmed antitumor activity in hematologic malignancies." | 2.79 | A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. ( Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E, 2014) |
| "Lenalidomide is an anti-angiogenic IMiD(®) immunomodulatory drug." | 2.76 | A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma. ( Carter, JS; Downs, LS, 2011) |
| "Thalidomide is an antiangiogenic agent with immune modulating potential." | 2.73 | A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. ( Abu-Ghazaleh, SZ; Argenta, PA; Bliss, RL; Boente, MP; Carson, LF; Chen, MD; Downs, LS; Geller, MA; Ghebre, R; Judson, PL; Nahhas, WA, 2008) |
| "Thalidomide is an anti-angiogenesis agent that has shown activity in some solid tumors." | 2.72 | Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. ( Chan, JK; Cheung, MK; Ciaravino, G; Husain, A; Manuel, MR; Teng, NN, 2006) |
| "Epithelial ovarian cancer (EOC) recurrence is common following treatment with cytoreductive surgery and adjuvant chemotherapy." | 1.35 | Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases. ( Leath, CA; Phippen, NT, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Selle, F | 1 |
| Sevin, E | 1 |
| Ray-Coquard, I | 1 |
| Mari, V | 1 |
| Berton-Rigaud, D | 1 |
| Favier, L | 1 |
| Fabbro, M | 1 |
| Lesoin, A | 1 |
| Lortholary, A | 1 |
| Pujade-Lauraine, E | 1 |
| Phippen, NT | 1 |
| Leath, CA | 1 |
| Carter, JS | 1 |
| Downs, LS | 2 |
| Chan, JK | 1 |
| Manuel, MR | 1 |
| Ciaravino, G | 1 |
| Cheung, MK | 1 |
| Husain, A | 1 |
| Teng, NN | 1 |
| Judson, PL | 1 |
| Argenta, PA | 1 |
| Ghebre, R | 1 |
| Geller, MA | 1 |
| Bliss, RL | 1 |
| Boente, MP | 1 |
| Nahhas, WA | 1 |
| Abu-Ghazaleh, SZ | 1 |
| Chen, MD | 1 |
| Carson, LF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Lipo[NCT01111903] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma[NCT00179712] | Phase 1/Phase 2 | 60 participants | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for thalidomide and Epithelial Neoplasms
| Article | Year |
|---|---|
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epit | 2014 |
A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug- | 2011 |
Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; California; Drug Administration Schedule | 2006 |
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Midd | 2008 |
1 other study available for thalidomide and Epithelial Neoplasms
| Article | Year |
|---|---|
Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2009 |